等待開盤 10-27 09:30:00 美东时间
-0.470
-5.54%
Predictive Oncology Inc. has expanded its leadership team and Board of Directors to support its new digital asset treasury strategy centered on the Aethir (ATH) token. Shawn Matthews, CEO of DNA Holdings Venture, Inc. and former CEO of Cantor Fitzgerald, has joined the Board. Thomas McLaughlin, CIO of DNA Holdings, is now the Chief Investment Officer, and Sara Turken, a biopharmaceutical veteran, has been appointed as General Counsel. The company...
10-14 12:00
Predictive Oncology ( ($POAI) ) has provided an update. On October 8, 2025, Pre...
10-09 00:27
The latest announcement is out from Predictive Oncology ( ($POAI) ). On Septemb...
09-29 22:18
Predictive Oncology (NASDAQ:POAI) announced on Monday the pricing of two private placement transactions to support its adoption of a digital asset treasury strategy under which the principal holding w...
09-29 21:40
Predictive Oncology Inc. announced two private placement transactions totaling $344.4 million to support its digital asset treasury strategy focused on accumulating ATH tokens from the Aethir ecosystem. The funds will be used to acquire ATH tokens for the treasury, support the company's core AI-driven drug discovery business, and establish a Strategic Compute Reserve. Aethir's decentralized GPU network provides cost-effective AI infrastructure, a...
09-29 13:07
Predictive Oncology (NASDAQ:POAI) on Thursday said it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock. Predictive Oncology’s common stock will continue ...
09-25 20:17
Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug development and discovery, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock. The
09-25 20:05
Predictive Oncology ( ($POAI) ) has issued an update. On September 9, 2025, Pre...
09-13 05:18
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying and validating new uses for existing drugs, today announced a
09-04 21:07